roxadustat
AstraZeneca to acquire FibroGen’s China unit for $160M
China, AstraZeneca, FibroGen, FibroGen ‘s, roxadustat
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry
FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials
FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained